Host |
Mouse |
Klon |
1F8 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:10 - 1:25 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
CD21
|
Diagnostic Biosystems |
1F8 |
0.5 ml |
Concentrate |
CE/IVD |
MOB028-05 |
-
|
Host |
Mouse |
Klon |
1F8 |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
CD21
|
Diagnostic Biosystems |
1F8 |
6 ml |
Ready-to-use |
CE/IVD |
PDM122 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM75 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil, lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human CR2 (CD21) protein fragment (around aa 44-196) |
Lokalisation |
Cell membrane |
CD21
|
Zeta Corporation |
ZM75 |
1 ml |
Concentrate |
CE/IVD |
Z2385ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM75 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil, lymph node. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human CR2 (CD21) protein fragment (around aa 44-196) |
Lokalisation |
Cell membrane |
CD21
|
Zeta Corporation |
ZM75 |
7 ml |
Ready-to-use |
CE/IVD |
Z2385MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM75 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil, lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human CR2 (CD21) protein fragment (around aa 44-196) |
Lokalisation |
Cell membrane |
CD21
|
Zeta Corporation |
ZM75 |
0.5 ml |
Concentrate |
CE/IVD |
Z2385MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM75 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil, lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human CR2 (CD21) protein fragment (around aa 44-196) |
Lokalisation |
Cell membrane |
CD21
|
Zeta Corporation |
ZM75 |
0.1 ml |
Concentrate |
CE/IVD |
Z2385MT |
-
|
Host |
Mouse |
Klon |
2G9 |
Format |
TCS |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:10 - 1:20 |
Isotyp |
Mouse IgG2a |
Verdünnung |
Recombinant human CD21 |
CD21 (EBV Receptor)
|
Zytomed Systems GmbH |
2G9 |
1 ml |
TCS |
RUO |
603-0638 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
MS, RT |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to C-terminus of human CD22 |
Lokalisation |
Cell membrane, Cytoplasm |
CD22
|
Zytomed Systems GmbH |
polyclonal |
0.1 ml |
Concentrate |
RUO |
503-19020 |
-
|
Host |
Rabbit |
Klon |
SP104 |
Format |
Concentrate |
Reaktivität |
DG |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Human tonsil, spleen, reactive lymph node |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide within Human CD22 aa 250-350 (extracellular) |
Lokalisation |
Cell Membrane |
CD22
|
Zytomed Systems GmbH |
SP104 |
0.5 ml |
Concentrate |
RUO |
503-4042 |
-
|
Host |
Rabbit |
Klon |
SP104 |
Format |
Concentrate |
Reaktivität |
DG |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Human tonsil, spleen, reactive lymph node |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide within Human CD22 aa 250-350 (extracellular) |
Lokalisation |
Cell Membrane |
CD22
|
Zytomed Systems GmbH |
SP104 |
1 ml |
Concentrate |
RUO |
503-4044 |
-
|
Host |
Rat |
Klon |
OX-97 |
Format |
Purified |
Methode |
FL |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rat IgG1 |
CD22
|
Zytomed Systems GmbH |
OX-97 |
250 µg |
Purified |
RUO |
603-0647 |
-
|
Host |
Mouse |
Klon |
BCLAM/1796 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Recombinant fragment of human CD22 protein (around aa 52 - 178) |
Lokalisation |
Cell membrane |
CD22
|
Biocare Medical |
BCLAM/1796 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3229B |
-
|
Host |
Mouse |
Klon |
BCLAM/1796 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Recombinant fragment of human CD22 protein (around aa 52 - 178) |
Lokalisation |
Cell membrane |
CD22
|
Biocare Medical |
BCLAM/1796 |
6 ml |
Ready-to-use |
CE/IVD |
API3229AA |
-
|
Host |
Monospecific Mouse |
Klon |
ZM183 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human BL-CAM/CD22 protein fragment (around aa52-178) |
Lokalisation |
Cytoplasm |
CD22
|
Zeta Corporation |
ZM183 |
1 ml |
Concentrate |
CE/IVD |
Z2496ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM183 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lymph node. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human BL-CAM/CD22 protein fragment (around aa52-178) |
Lokalisation |
Cytoplasm |
CD22
|
Zeta Corporation |
ZM183 |
7 ml |
Ready-to-use |
CE/IVD |
Z2496MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM183 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human BL-CAM/CD22 protein fragment (around aa52-178) |
Lokalisation |
Cytoplasm |
CD22
|
Zeta Corporation |
ZM183 |
0.5 ml |
Concentrate |
CE/IVD |
Z2496MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM183 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human BL-CAM/CD22 protein fragment (around aa52-178) |
Lokalisation |
Cytoplasm |
CD22
|
Zeta Corporation |
ZM183 |
0.1 ml |
Concentrate |
CE/IVD |
Z2496MT |
-
|
Host |
Mouse |
Klon |
1B12 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:10 - 1:20 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
CD23
|
Diagnostic Biosystems |
1B12 |
1 ml |
Concentrate |
CE/IVD |
MOB294 |
-
|
Host |
Mouse |
Klon |
1B12 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:10 - 1:20 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
CD23
|
Diagnostic Biosystems |
1B12 |
0.1 ml |
Concentrate |
CE/IVD |
MOB294-01 |
-
|
Host |
Mouse |
Klon |
1B12 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:10 - 1:20 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
CD23
|
Diagnostic Biosystems |
1B12 |
0.5 ml |
Concentrate |
CE/IVD |
MOB294-05 |
-
|
Host |
Mouse |
Klon |
1B12 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
CD23
|
Diagnostic Biosystems |
1B12 |
6 ml |
Ready-to-use |
CE/IVD |
PDM143 |
-
|
Host |
Rabbit |
Klon |
SP23 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cell Membrane |
CD23
|
Diagnostic Biosystems |
SP23 |
1 ml |
Concentrate |
CE/IVD |
RMAB013 |
-
|
Host |
Rabbit |
Klon |
SP23 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cell Membrane |
CD23
|
Diagnostic Biosystems |
SP23 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB013-01 |
-
|
Host |
Rabbit |
Klon |
SP23 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cell Membrane |
CD23
|
Diagnostic Biosystems |
SP23 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB013-05 |
-
|
Host |
Rabbit |
Klon |
SP23 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cell Membrane |
CD23
|
Diagnostic Biosystems |
SP23 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD013 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM209 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:50 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant fragment (around aa 48-321) of human FCER2/CD23 protein |
Lokalisation |
Cell membrane |
CD23
|
Zeta Corporation |
ZM209 |
1 ml |
Concentrate |
CE/IVD |
Z2545ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM209 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant fragment (around aa 48-321) of human FCER2/CD23 protein |
Lokalisation |
Cell membrane |
CD23
|
Zeta Corporation |
ZM209 |
7 ml |
Ready-to-use |
CE/IVD |
Z2545MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM209 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:50 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant fragment (around aa 48-321) of human FCER2/CD23 protein |
Lokalisation |
Cell membrane |
CD23
|
Zeta Corporation |
ZM209 |
0.5 ml |
Concentrate |
CE/IVD |
Z2545MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM209 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:50 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant fragment (around aa 48-321) of human FCER2/CD23 protein |
Lokalisation |
Cell membrane |
CD23
|
Zeta Corporation |
ZM209 |
0.1 ml |
Concentrate |
CE/IVD |
Z2545MT |
-
|
Host |
Mouse |
Klon |
SN3 |
Format |
Purified |
Methode |
F, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Glycoprotein purified from human NALM-1 cell line |
CD24
|
Zytomed Systems GmbH |
SN3 |
200 µg |
Purified |
RUO |
603-0677 |
-
|
Host |
Mouse |
Klon |
SN3 |
Format |
Purified |
Methode |
F, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Glycoprotein purified from human NALM-1 cell line |
CD24
|
Zytomed Systems GmbH |
SN3 |
100 µg |
Purified |
RUO |
603-0678 |
-
|
Host |
Rabbit |
Klon |
SP176 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from the C-terminus of human CD25 protein |
Lokalisation |
Cell Membrane |
CD25
|
Zytomed Systems GmbH |
SP176 |
0.1 ml |
Concentrate |
RUO |
503-4760 |
-
|
Host |
Rabbit |
Klon |
SP176 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from the C-terminus of human CD25 protein |
Lokalisation |
Cell Membrane |
CD25
|
Zytomed Systems GmbH |
SP176 |
0.5 ml |
Concentrate |
RUO |
503-4762 |
-
|
Host |
Rabbit |
Klon |
SP176 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from the C-terminus of human CD25 protein |
Lokalisation |
Cell Membrane |
CD25
|
Zytomed Systems GmbH |
SP176 |
1 ml |
Concentrate |
RUO |
503-4764 |
-
|
Host |
Mouse |
Klon |
ZM466 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon, neurofibroma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b |
Verdünnung |
Recombinant protein corresponding to the external domain of human interleukin-2 receptor protein |
Lokalisation |
Cytoplasmic |
CD25
|
Zeta Corporation |
ZM466 |
0.1 ml |
Concentrate |
RUO |
Z2817MT-R |
-
|
Host |
Mouse |
Klon |
M-A261 |
Format |
Purified |
Methode |
F, IP, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human T cell leukemia cells (T-CLL) |
CD26 (Dipeptidyl Peptidase IV)
|
Zytomed Systems GmbH |
M-A261 |
100 µg |
Purified |
RUO |
603-0710 |
-
|
Host |
Mouse |
Klon |
4B7R |
Format |
Purified |
Methode |
P, IP, FL |
Vorbehandlung |
(Trypsin) |
Isotyp |
Mouse IgG1 |
Verdünnung |
Occular melanoma cell line V+B2 |
CD29 (Integrin beta 1)
|
Zytomed Systems GmbH |
4B7R |
200 µg |
Purified |
RUO |
603-0748 |
-
|
Host |
Mouse |
Klon |
4B7R |
Format |
Purified |
Methode |
P, IP, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Occular melanoma cell line V+B2 |
CD29 (Integrin beta 1)
|
Zytomed Systems GmbH |
4B7R |
100 µg |
Purified |
RUO |
603-0749 |
-
|
Host |
Mouse |
Klon |
Ber-H2 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hodgkin lymphoma or anaplastic large cell lymphoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Co cell line established from a patient with Hodgkin's disease of T-cell lineage |
Lokalisation |
Cell membrane and Cytoplasm |
CD30
|
Zeta Corporation |
Ber-H2 |
1.0 ml |
Concentrate |
CE/IVD |
Z2101ML |
-
|
Host |
Mouse |
Klon |
Ber-H2 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hodgkin lymphoma or anaplastic large cell lymphoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Co cell line established from a patient with Hodgkin's disease of T-cell lineage |
Lokalisation |
Cell membrane and Cytoplasm |
CD30
|
Zeta Corporation |
Ber-H2 |
7 ml |
Ready-to-use |
CE/IVD |
Z2101MP |
-
|
Host |
Mouse |
Klon |
Ber-H2 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hodgkin lymphoma or anaplastic large cell lymphoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Co cell line established from a patient with Hodgkin's disease of T-cell lineage |
Lokalisation |
Cell membrane and Cytoplasm |
CD30
|
Zeta Corporation |
Ber-H2 |
0.5 ml |
Concentrate |
CE/IVD |
Z2101MS |
-
|
Host |
Mouse |
Klon |
Ber-H2 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hodgkin lymphoma or anaplastic large cell lymphoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Co cell line established from a patient with Hodgkin's disease of T-cell lineage |
Lokalisation |
Cell membrane and Cytoplasm |
CD30
|
Zeta Corporation |
Ber-H2 |
0.1 ml |
Concentrate |
CE/IVD |
Z2101MT |
-
|
Host |
Rabbit |
Klon |
ZR248 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hodgkin lymphoma or anaplastic large cell lymphoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant human full-length TNFRSF8 protein (CD30) |
Lokalisation |
Cell membrane and Cytoplasm |
CD30
|
Zeta Corporation |
ZR248 |
1 ml |
Concentrate |
CE/IVD |
Z2489RL |
-
|
Host |
Rabbit |
Klon |
ZR248 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hodgkin lymphoma or anaplastic large cell lymphoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant human full-length TNFRSF8 protein (CD30) |
Lokalisation |
Cell membrane and Cytoplasm |
CD30
|
Zeta Corporation |
ZR248 |
7 ml |
Ready-to-use |
CE/IVD |
Z2489RP |
-
|
Host |
Rabbit |
Klon |
ZR248 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hodgkin lymphoma or anaplastic large cell lymphoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant human full-length TNFRSF8 protein (CD30) |
Lokalisation |
Cell membrane and Cytoplasm |
CD30
|
Zeta Corporation |
ZR248 |
0.5 ml |
Concentrate |
CE/IVD |
Z2489RS |
-
|
Host |
Rabbit |
Klon |
ZR248 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hodgkin lymphoma or anaplastic large cell lymphoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant human full-length TNFRSF8 protein (CD30) |
Lokalisation |
Cell membrane and Cytoplasm |
CD30
|
Zeta Corporation |
ZR248 |
0.1 ml |
Concentrate |
CE/IVD |
Z2489RT |
-
|
Host |
Mouse |
Klon |
JC70A |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Placenta. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Preparation of a spleen from a patient with hairy cell leukemia |
Lokalisation |
Cell membrane |
CD31
|
Zeta Corporation |
JC70A |
1.0 ml |
Concentrate |
CE/IVD |
Z2136ML |
-
|
Host |
Mouse |
Klon |
JC70A |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Placenta. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Preparation of a spleen from a patient with hairy cell leukemia |
Lokalisation |
Cell membrane |
CD31
|
Zeta Corporation |
JC70A |
7 ml |
Ready-to-use |
CE/IVD |
Z2136MP |
-
|
Host |
Mouse |
Klon |
JC70A |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Placenta. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Preparation of a spleen from a patient with hairy cell leukemia |
Lokalisation |
Cell membrane |
CD31
|
Zeta Corporation |
JC70A |
0.5 ml |
Concentrate |
CE/IVD |
Z2136MS |
-
|
Host |
Mouse |
Klon |
JC70A |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Placenta. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Preparation of a spleen from a patient with hairy cell leukemia |
Lokalisation |
Cell membrane |
CD31
|
Zeta Corporation |
JC70A |
0.1 ml |
Concentrate |
CE/IVD |
Z2136MT |
-
|